| Authors: |
Lopez JS; Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK., Harrington KJ; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, UK., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Lee KW; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Postel-Vinay S; Institut Gustave Roussy, Villejuif, France., Thomas JS; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Lukashchuk N; Translational Medicine Early Oncology, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK., Willis SE; Cancer Biomarker Development, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK., Irurzun-Arana I; Clinical Pharmacology Quantitative Pharmacology, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.; GSK, Madrid, Spain., Webb B; Early Oncology Statistics, Biometrics Oncology, Oncology R&D, AstraZeneca, Cambridge, UK., Nehra J; Late Oncology Development, GI Cancer and Strategy, Oncology R&D, AstraZeneca, Waltham, MA, USA., Lau A; UK - SM Bioscience Team, Oncology Targeted Discovery, Oncology R&D, AstraZeneca, Cambridge, UK., Loembé AB; Early Oncology Clinical, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Experimental Medicine Oncology department, Boehringer-Ingelheim, Ingelheim, Germany., Dean E; Early ICA Projects, Early Oncology Development, Oncology R&D, AstraZeneca, Cambridge, UK., Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@manchester.ac.uk. |
